Immunome, Inc. (IMNM)
19.23
-0.08
(-0.41%)
USD |
NASDAQ |
Oct 07, 15:43
Immunome Enterprise Value : 1.672B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 1.672B |
| October 05, 2026 | 1.883B |
| October 02, 2026 | 1.852B |
| October 01, 2026 | 1.851B |
| September 30, 2026 | 1.921B |
| September 29, 2026 | 1.964B |
| September 28, 2026 | 1.941B |
| September 25, 2026 | 1.910B |
| September 24, 2026 | 2.015B |
| September 23, 2026 | 2.231B |
| September 22, 2026 | 2.402B |
| September 21, 2026 | 2.325B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.196B |
| September 16, 2026 | 2.142B |
| September 15, 2026 | 2.198B |
| September 14, 2026 | 2.266B |
| September 11, 2026 | 2.280B |
| September 10, 2026 | 2.314B |
| September 09, 2026 | 2.444B |
| September 08, 2026 | 2.522B |
| September 04, 2026 | 2.517B |
| September 03, 2026 | 2.562B |
| September 02, 2026 | 2.581B |
| September 01, 2026 | 2.551B |
| Date | Value |
|---|---|
| August 31, 2026 | 2.590B |
| August 28, 2026 | 2.608B |
| August 27, 2026 | 2.756B |
| August 26, 2026 | 2.742B |
| August 25, 2026 | 2.814B |
| August 24, 2026 | 2.658B |
| August 21, 2026 | 2.716B |
| August 20, 2026 | 2.666B |
| August 19, 2026 | 2.864B |
| August 18, 2026 | 2.607B |
| August 17, 2026 | 2.589B |
| August 14, 2026 | 2.567B |
| August 13, 2026 | 2.478B |
| August 12, 2026 | 2.656B |
| August 11, 2026 | 2.459B |
| August 10, 2026 | 2.395B |
| August 07, 2026 | 2.320B |
| August 06, 2026 | 2.410B |
| August 05, 2026 | 2.376B |
| August 04, 2026 | 2.324B |
| August 03, 2026 | 2.091B |
| July 31, 2026 | 2.063B |
| July 30, 2026 | 2.099B |
| July 29, 2026 | 2.103B |
| July 28, 2026 | 2.115B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.460B |
| Erasca, Inc. | 4.246B |
| Oncolytics Biotech, Inc. | 70.87M |
| Sangamo Therapeutics, Inc. | 49.74M |
| Sarepta Therapeutics, Inc. | 2.086B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.13M |
| Total Expenses (Quarterly) | 73.13M |
| EPS Diluted (Quarterly) | -0.6456 |
| Earnings Yield | -13.14% |
| Normalized Earnings Yield | -12.75 |